Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|February 24, 2026

Protocol-Driven eSource Advances Study Efficiency

Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.

In a recent video interview with Applied Clinical Trials, Jonathan Andrus, co-CEO of CRIO, discussed how 2026 is expected to mark a continued shift toward site-based technologies and protocol-driven eSource to improve data quality, compliance, and trial efficiency. He emphasized the importance of capturing high-quality data at the point of patient encounter, reducing fragmentation across sites, and enabling real-time data access and monitoring. Andrus also highlighted the growing need for cross-functional collaboration during protocol design, stronger governance across the data lifecycle, and increased use of AI to streamline study build, data review, and operational workflows.

Editor's note: This transcript is a lightly edited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.

ACT: How do you expect eClinical platforms to evolve in 2026 to better support data quality, oversight, and study efficiency?

Andrus: Building on that, one of the key elements will be sponsors providing sites with protocol-driven eSource tools—essentially electronic source data collection systems based on standardized templates derived directly from the study protocol.

What that means is taking the protocol and translating it into structured data collection templates that are distributed across all participating sites. This ensures consistency in how data are collected and reinforces quality at the point of patient encounter.

These tools include built-in logic, edit checks, and cross-form validation, so when a coordinator is sitting with a patient, they can be confident the data being captured aligns with protocol requirements. That’s a major shift from current approaches, where EHRs may contain relevant data but are not tied to protocol-specific requirements, and paper systems have no logic or validation at all.

At the same time, it’s important that sites maintain flexibility. They still need the ability to incorporate local workflows or procedures—such as pre-screening steps—into the system. So the balance is standardization through central templates, combined with flexibility for site-specific needs.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.